| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.009 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.15 | 0.009 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.009 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.16 | 0.01 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.17 | 0.01 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | -0.095 | 0.01 |